

ALLERGAN INC  
Form SC 13D/A  
July 17, 2014

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**(Rule 13d-101)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a)**

**AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a)**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**(Amendment No. 6)\***

**Allergan, Inc.**

**(Name of Issuer)**

**COMMON STOCK, \$0.01 PAR VALUE**

**(Title of Class of Securities)**

**018490102**

**(CUSIP Number)**

**Valeant Pharmaceuticals International, Inc.**

**Robert R. Chai-Onn**

**2150 St. Elzéar Blvd. West**

**Laval, Quebec**

Edgar Filing: ALLERGAN INC - Form SC 13D/A

**Canada, H7L 4A8**

**(514) 744-6792**

*With a copy to:*

**Alison S. Ressler**

**Sullivan & Cromwell LLP**

**1888 Century Park East**

**Los Angeles, California 90067-1725**

**(310) 712-6600**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**July 15, 2014**

**(Date of Event which Requires Filing of This Statement)**

Edgar Filing: ALLERGAN INC - Form SC 13D/A

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this Schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box “.

*Note.* Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* § 240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the Notes).

CUSIP No. 018490102

1. NAME OF REPORTING PERSON

Valeant Pharmaceuticals International, Inc.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions):

(a)  (b)

3. SEC Use Only

4. SOURCE OF FUNDS (see instructions)

AF, WC

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

6. CITIZENSHIP OR PLACE OF ORGANIZATION

British Columbia, Canada

7. SOLE VOTING POWER

100

Number Of 8. SHARED VOTING POWER

Shares  
Beneficially  
Owned By

Each Reporting 28,878,538

Person 9. SOLE DISPOSITIVE POWER

With

100

10. SHARED DISPOSITIVE POWER

597,431

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

28,878,638

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

9.7%<sup>1</sup>

14. TYPE OF REPORTING PERSON (see instructions)

HC

(1) This calculation is based on 296,910,449 shares of Common Stock, par value \$0.01 per share (the Common Stock ), of Allergan, Inc. (the Issuer ) outstanding as of June 30, 2014 as reported in the Issuer's Preliminary Proxy Statement on Schedule 14A filed on July 15, 2014.

CUSIP No. 018490102

1. NAME OF REPORTING PERSON

Valeant Pharmaceuticals International

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions):

(a)  (b)

3. SEC Use Only

4. SOURCE OF FUNDS (see instructions)

WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

7. SOLE VOTING POWER

-0-

Number Of 8. SHARED VOTING POWER

Shares  
Beneficially  
Owned By

Each Reporting 28,878,538

Person 9. SOLE DISPOSITIVE POWER

With

-0-

10. SHARED DISPOSITIVE POWER

597,431

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

28,878,638

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

9.7%<sup>1</sup>

14. TYPE OF REPORTING PERSON (see instructions)

CO

(1) This calculation is based on 296,910,449 shares of Common Stock, par value \$0.01 per share (the Common Stock ), of Allergan, Inc. (the Issuer ) outstanding as of June 30, 2014 as reported in the Issuer's Preliminary Proxy Statement on Schedule 14A filed on July 15, 2014.

This Amendment No. 6 relates to the Schedule 13D filed on April 21, 2014, as amended prior to the date of this Amendment No. 6 (as so amended, the Original 13D ), by Valeant Pharmaceuticals International, Inc., a corporation continued under the laws of British Columbia (Valeant ), and Valeant Pharmaceuticals International, a Delaware corporation and a wholly owned subsidiary of Valeant (Valeant USA and, together with Valeant, the Reporting Persons ), relating to common shares, par value \$0.01 (the Common Stock ), of Allergan, Inc., a Delaware corporation (the Issuer ). Capitalized terms used but not defined herein shall have the meaning set forth in the Original 13D.

**ITEM 6 Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 6 of the Original 13D is hereby amended and supplemented by adding the following information:

On July 15, 2014, Valeant and Pershing Square entered into an indemnification letter agreement relating to Valeant's previously announced exchange offer. The letter agreement is filed as Exhibit 99.1 and is incorporated by reference into this Item 6 as if restated in full.

**ITEM 7 Material to be Filed as Exhibits**

**Exhibit**

**Document Description**

99.1	Letter Agreement between Valeant Pharmaceuticals International, Inc. and Pershing Square Capital Management, L.P., dated July 15, 2014.
------	-----------------------------------------------------------------------------------------------------------------------------------------



**SIGNATURE**

After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this amendment is true, complete and correct.

Dated: July 17, 2014

**VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.**

By: /s/ Robert R. Chai-Onn  
Name: Robert R. Chai-Onn  
Title: Executive Vice President, General  
Counsel and Chief Legal Officer, Head  
of Corporate and Business  
Development

**VALEANT PHARMACEUTICALS  
INTERNATIONAL**

By: /s/ Robert R. Chai-Onn  
Name: Robert R. Chai-Onn  
Title: Executive Vice President, General  
Counsel and Corporate Secretary

**EXHIBIT INDEX**

**Exhibit**

**Document Description**

99.1 Letter Agreement between Valeant Pharmaceuticals International, Inc. and Pershing Square Capital Management, L.P., dated July 15, 2014.